Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rigetti Computing Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.23 (market cap $29.97B), while Rigetti Computing Inc trades at $18.55 (market cap $6.15B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.9× Rigetti Computing Inc's market cap. Which is the better fit depends on your goals.
| ALNY | RGTI | |
|---|---|---|
Market Cap | $29.97B | $6.15B |
Sector | Health | Technology |
52-Week High | $491.22 | $56.34 |
52-Week Low | $205.48 | $12.90 |
Enterprise Value | $27.93B | $5.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rigetti Computing (RGTI) trades at $18.42, up 4.36% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported Q2 2026 revenue growth of 185% to $5.1 million, beating estimates, but posted a net loss of $0.05 per share, missing expectations. Despite heavy operating losses and negative margins, analyst sentiment remains strongly positive with 85.7% recommending Buy, driven by government backing and quantum computing potential.
The outlook for RGTI is high-risk, high-reward, offering exposure to the emerging quantum computing sector with significant government and commercial interest. However, persistent negative profitability, high cash burn, and intense competition from peers like IonQ pose substantial risks to shareholder value. Investment suitability is limited to those tolerant of speculative, early-stage company volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
